Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.28 Billion USD | -4.28% |
| 2022 | 14.92 Billion USD | 7.37% |
| 2021 | 13.9 Billion USD | 2.14% |
| 2020 | 13.6 Billion USD | 17.88% |
| 2019 | 11.54 Billion USD | 7.13% |
| 2018 | 10.77 Billion USD | 25.52% |
| 2017 | 8.58 Billion USD | 12.25% |
| 2016 | 7.64 Billion USD | -3.34% |
| 2015 | 7.91 Billion USD | 19.77% |
| 2014 | 6.6 Billion USD | 0.75% |
| 2013 | 6.55 Billion USD | 4.73% |
| 2012 | 6.26 Billion USD | 9.65% |
| 2011 | 5.71 Billion USD | 8.08% |
| 2010 | 5.28 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 14.34 Billion USD | 0.43% |
| 2024 Q3 | 14.35 Billion USD | 1.36% |
| 2024 Q2 | 14.16 Billion USD | -1.28% |
| 2023 Q2 | 13.74 Billion USD | -0.04% |
| 2023 Q1 | 13.75 Billion USD | -7.85% |
| 2023 Q4 | 14.28 Billion USD | 1.28% |
| 2023 Q3 | 14.1 Billion USD | 2.6% |
| 2023 FY | 14.28 Billion USD | -4.28% |
| 2022 Q2 | 13.77 Billion USD | -0.65% |
| 2022 FY | 14.92 Billion USD | 7.37% |
| 2022 Q4 | 14.92 Billion USD | 9.15% |
| 2022 Q3 | 13.67 Billion USD | -0.7% |
| 2022 Q1 | 13.86 Billion USD | -0.29% |
| 2021 FY | 13.9 Billion USD | 2.14% |
| 2021 Q4 | 13.9 Billion USD | 1.42% |
| 2021 Q3 | 13.7 Billion USD | -2.59% |
| 2021 Q2 | 14.06 Billion USD | 1.98% |
| 2021 Q1 | 13.79 Billion USD | 1.37% |
| 2020 Q3 | 13.72 Billion USD | 5.02% |
| 2020 Q2 | 13.06 Billion USD | 13.37% |
| 2020 Q4 | 13.6 Billion USD | -0.85% |
| 2020 FY | 13.6 Billion USD | 17.88% |
| 2020 Q1 | 11.52 Billion USD | -0.15% |
| 2019 Q3 | 11.27 Billion USD | 2.6% |
| 2019 FY | 11.54 Billion USD | 7.13% |
| 2019 Q4 | 11.54 Billion USD | 2.42% |
| 2019 Q1 | 10.88 Billion USD | 0.98% |
| 2019 Q2 | 10.98 Billion USD | 0.95% |
| 2018 Q3 | 10.45 Billion USD | 21.57% |
| 2018 Q4 | 10.77 Billion USD | 3.04% |
| 2018 FY | 10.77 Billion USD | 25.52% |
| 2018 Q2 | 8.6 Billion USD | -1.0% |
| 2018 Q1 | 8.69 Billion USD | 1.21% |
| 2017 Q3 | 9.28 Billion USD | 19.05% |
| 2017 Q1 | 7.64 Billion USD | 0.0% |
| 2017 FY | 8.58 Billion USD | 12.25% |
| 2017 Q4 | 8.58 Billion USD | -7.56% |
| 2017 Q2 | 7.8 Billion USD | 2.0% |
| 2016 Q2 | 7.51 Billion USD | 0.87% |
| 2016 Q3 | 7.71 Billion USD | 2.62% |
| 2016 Q4 | 7.64 Billion USD | -0.86% |
| 2016 FY | 7.64 Billion USD | -3.34% |
| 2016 Q1 | 7.45 Billion USD | -5.81% |
| 2015 Q3 | 6.68 Billion USD | 1.33% |
| 2015 FY | 7.91 Billion USD | 19.77% |
| 2015 Q4 | 7.91 Billion USD | 18.35% |
| 2015 Q2 | 6.59 Billion USD | 2.61% |
| 2015 Q1 | 6.43 Billion USD | -2.68% |
| 2014 Q3 | 6.52 Billion USD | 0.08% |
| 2014 Q4 | 6.6 Billion USD | 1.23% |
| 2014 FY | 6.6 Billion USD | 0.75% |
| 2014 Q1 | 6.4 Billion USD | -2.36% |
| 2014 Q2 | 6.52 Billion USD | 1.86% |
| 2013 Q2 | 6.26 Billion USD | 1.94% |
| 2013 Q3 | 6.25 Billion USD | -0.03% |
| 2013 Q1 | 6.14 Billion USD | -1.92% |
| 2013 FY | 6.55 Billion USD | 4.73% |
| 2013 Q4 | 6.55 Billion USD | 4.78% |
| 2012 FY | 6.26 Billion USD | 9.65% |
| 2012 Q1 | 5.9 Billion USD | 3.41% |
| 2012 Q2 | 5.8 Billion USD | -1.79% |
| 2012 Q3 | 5.9 Billion USD | 1.79% |
| 2012 Q4 | 6.26 Billion USD | 6.06% |
| 2011 Q4 | 5.71 Billion USD | 0.0% |
| 2011 FY | 5.71 Billion USD | 8.08% |
| 2010 FY | 5.28 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.47 Billion USD | -311.396% |
| Bausch Health Companies Inc. | 27.35 Billion USD | 47.766% |
| Catalent, Inc. | 9.75 Billion USD | -46.478% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -678.571% |
| Elanco Animal Health Incorporated | 14.36 Billion USD | 0.529% |
| Perrigo Company plc | 10.8 Billion USD | -32.166% |
| Teva Pharmaceutical Industries Limited | 43.47 Billion USD | 67.143% |